KYTX offering history
Every offering-related filing in Kyverna Therapeutics, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 185 filings back to Oct 5, 2023.
| Date | Filing | What it means | |
|---|---|---|---|
| Apr 2, 2026 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Apr 2, 2026 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Mar 26, 2026 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Dec 18, 2025 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Dec 17, 2025 | FWP → | MARKETING | Free-writing prospectus — offering being marketed |
| Dec 15, 2025 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Apr 15, 2025 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Apr 15, 2025 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Mar 27, 2025 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Feb 8, 2024 | 424B4 → | EXECUTED | Final prospectus — offering priced (typical for IPOs and marketed share deals) |
| Feb 7, 2024 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Feb 6, 2024 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Feb 1, 2024 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Jan 16, 2024 | S-1 → | REGISTERED | S-1 registration — capacity to sell shares, not a sale yet |
Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
KYTX offering FAQ
When did KYTX last execute an offering?
Per SEC filings, Kyverna Therapeutics, Inc.'s most recent priced offering document is a 424B5 filed 2026-04-02. Note a 424B takedown can price shares or notes (debt) — the linked document says which.
When did KYTX last announce or register an offering?
The most recent registration is a S-3 filed 2026-03-26. A registration is capacity to sell shares — not a sale.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.